The research was led by a multidisciplinary team at Guangdong Provincial People’s Hospital affiliated with Southern Medical University, together with collaborators at several other Chinese institutions. The investigators combined quantitative proteomics, a technique that measures the full complement of proteins in cells, with N4-acetylcytidine RNA immunoprecipitation sequencing, or acRIP-seq, which maps a specific chemical tag deposited onto messenger RNA molecules. They also drew on CRISPR-based dependency screens, which systematically disable genes one by one to reveal which ones cancer cells cannot live without. This triple lens allowed them to sift through the molecular chaos of radiation-resistant glioblastoma cells and pinpoint NAT10 as a standout culprit whose activity correlates with both treatment failure and poor patient survival.

NAT10 is what scientists call a writer of the epitranscriptome, the layer of chemical modifications that adorn RNA molecules without altering the underlying genetic sequence. Specifically, NAT10 installs a modification called N4-acetylcytidine, abbreviated ac4C, onto messenger RNAs. These chemical tags act like molecular Post-it notes, influencing how stable an RNA molecule is and how efficiently it is translated into protein. While aberrant RNA modifications have increasingly been implicated in cancer progression, the specific epitranscriptomic vulnerabilities that allow glioblastoma to withstand radiation had remained largely unexplored. The new study fills that gap with an unusually detailed mechanistic account.

At the heart of the discovery lies a gene called SLC7A11, which encodes a cellular transporter responsible for importing cystine, a building block of the antioxidant glutathione. Using acRIP-seq, the researchers found that NAT10 deposits ac4C marks directly onto SLC7A11 messenger RNA. These marks stabilize the transcript and enhance its translation into protein, effectively turning up the volume on the cell’s antioxidant machinery. The consequences are profound for a tumor facing radiation. Ionizing radiation kills cells in part by generating reactive oxygen species that damage DNA and membranes. A cell brimming with glutathione and the protective enzyme glutathione peroxidase 4, or GPX4, is well armored against this oxidative barrage, and elevated SLC7A11 provides exactly that armor.

The study goes further by connecting this antioxidant shield to a form of cell death that has captivated cancer biologists in recent years: ferroptosis. Ferroptosis is an iron-dependent demise driven by the accumulation of lipid peroxides in cellular membranes, and it can be unleashed when antioxidant defenses, particularly the glutathione-GPX4 axis, falter. The researchers demonstrated that glioblastoma cells with high NAT10 activity evade radiation-induced ferroptosis by keeping SLC7A11 levels high. When the team used a catalytically inactive mutant of NAT10, designated NAT10-G641E, they confirmed that the enzyme’s acetylation activity, not some unrelated function, was responsible for the effect. RNA stability assays and polysome profiling, which measure how actively messenger RNAs are being translated, reinforced the causal chain from NAT10, through ac4C on SLC7A11 mRNA, to antioxidant capacity and ferroptosis resistance.

Perhaps the most striking finding is that interfering with NAT10 does more than simply make tumor cells easier to kill. When glioblastoma cells lose their NAT10-driven antioxidant defenses and undergo ferroptosis in response to radiation, they die in a way that rings alarm bells for the immune system. This phenomenon, known as immunogenic cell death, involves the release of damage-associated molecular patterns such as calreticulin, adenosine triphosphate, and high mobility group box 1, which promote the maturation of dendritic cells and activate cytotoxic CD8-positive T cells. In orthotopic mouse models, where tumors are grown inside the brain, NAT10 inhibition triggered what the authors describe as a cold-to-hot transformation of the tumor microenvironment, converting an immunosuppressive, T-cell-poor landscape into one teeming with tumor-fighting immune cells.

This immunological dimension matters because glioblastoma has been notoriously refractory to immunotherapy. Its brain location, the blood-brain barrier, and a profoundly immunosuppressive microenvironment rich in suppressive myeloid cells have conspired to defeat most attempts to harness the immune system against it. A therapy that simultaneously lowers the biochemical threshold for radiation killing and recruits an immune response offers a two-pronged attack that could be more potent than either approach alone. The findings suggest that ferroptosis, long studied primarily as a cell-intrinsic vulnerability, can serve as a bridge between radiotherapy and anticancer immunity in the brain.

Translating this biology into a therapy required a practical inhibitor of NAT10. Existing NAT10 inhibitors carry toxicity concerns that limit their appeal, so the research team turned to computational drug repurposing, screening approved drugs for the ability to disrupt the NAT10-ac4C-SLC7A11 axis. Their search converged on pemetrexed, an antifolate chemotherapy already in clinical use for other cancers. In their experiments, pemetrexed suppressed NAT10 activity, destabilized SLC7A11 messenger RNA, and stripped glioblastoma cells of their glutathione supply. When combined with radiotherapy in mouse models, pemetrexed produced profound synergistic survival benefits, validating the repurposing strategy and offering a potentially safer path to the clinic than purpose-built NAT10 inhibitors.

The study also carries prognostic weight for patients. By analyzing patient cohorts, the researchers showed that NAT10 expression correlates with poor overall survival and poor progression-free survival in glioblastoma, positioning the enzyme as both a biomarker of aggressive disease and a therapeutic target. The work received ethics approval from the review board of Guangdong Provincial People’s Hospital and the Animal Ethics Committee of Nanfang Hospital, and it was funded by the National Natural Science Foundation of China along with provincial and municipal science foundations in Guangdong and Guangzhou.

For a cancer that has seen precious few therapeutic advances in decades, the convergence of RNA modification biology, ferroptosis, and immunology in a single actionable axis is notable. The results imply that doctors might one day stratify glioblastoma patients by NAT10 activity, administer pemetrexed alongside standard radiotherapy to collapse the tumors’ antioxidant defenses, and thereby convert a silently resistant tumor into an immunologically visible one. Considerable work remains before such a regimen reaches patients, including clinical trials to establish dosing, safety, and efficacy in humans with brain tumors. But the study provides a rigorous mechanistic foundation for that effort, demonstrating with molecular precision how a single RNA writer enzyme can govern whether radiation becomes a lethal blow to a tumor or merely a wound that heals. In the difficult landscape of glioblastoma research, findings of this clarity are rare, and they renew hope that even the most radiation-resistant cancers can be made vulnerable through a deeper understanding of their chemistry.

Subject of Research: NAT10-mediated RNA acetylation driving glioblastoma radioresistance through suppression of immunogenic ferroptosis

Article Title: N-acetyltransferase 10 promotes glioblastoma radioresistance by suppressing immunogenic ferroptosis through N4-acetylcytidine of SLC7A11 mRNA

Article References: Hu, S., Cheng, J., Liu, Y., Chen, C., Qiu, R., Liu, Y., Zhang, Q., Xie, Y., Wan, B., Tan, P., Xie, D., Lei, Y., Luo, H., Feng, W., Deng, Y., Hua, X., Ren, C., & Du, S. (2026). N-acetyltransferase 10 promotes glioblastoma radioresistance by suppressing immunogenic ferroptosis through N4-acetylcytidine of SLC7A11 mRNA. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03822-3

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03822-3

Keywords: glioblastoma, NAT10, N4-acetylcytidine, radioresistance, ferroptosis, SLC7A11, pemetrexed, immunogenic cell death, epitranscriptomics, radiotherapy, tumor microenvironment, drug repurposing